Emergent Biosolutions Inc (EBS) 13F Investor Activity Report (Q2 2026)

EBS ranks #3010 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

199 institutions disclose a position in EBS, but none treat it as a major bet — even Oak Hill Advisors LP, its most concentrated holder, allocates just 1.3% of its own portfolio to it.

Israel Englander has added to its EBS position for two straight quarters, increasing it by $6.0M to reach $9.0M today.

Palisade Capital Management, LP has trimmed its EBS position for two straight quarters, cutting it by $11.3M while still holding $4.3M.

EBS is up 3.9% today, and institutions have been net buyers of $31.5M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

EBS reported a net loss of $176.8M over the trailing twelve months.

• Not yet profitable — net loss of $176.8M over the trailing twelve months
• Revenue declined 9.6% year over year
• Net income declined year over year, from $139.5M to -$176.8M
• Generated $170.6M in positive operating cash flow
• Current ratio of 5.01x — enough short-term assets to cover short-term liabilities
• Liabilities run 1.52x equity — within a conventional range